Riccardo Perbellini

1.4k total citations
40 papers, 781 citations indexed

About

Riccardo Perbellini is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Riccardo Perbellini has authored 40 papers receiving a total of 781 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Epidemiology, 34 papers in Hepatology and 2 papers in Infectious Diseases. Recurrent topics in Riccardo Perbellini's work include Hepatitis C virus research (31 papers), Liver Disease Diagnosis and Treatment (28 papers) and Hepatitis B Virus Studies (19 papers). Riccardo Perbellini is often cited by papers focused on Hepatitis C virus research (31 papers), Liver Disease Diagnosis and Treatment (28 papers) and Hepatitis B Virus Studies (19 papers). Riccardo Perbellini collaborates with scholars based in Italy, France and Singapore. Riccardo Perbellini's co-authors include Maurizio C. Capogrossi, Fabio Martelli, Simona Greco, Rosanna Cardani, G. Meola, Pietro Lampertico, Marta Borghi, Elisabetta Degasperi, Roberta D’Ambrosio and F. Facchetti and has published in prestigious journals such as PLoS ONE, Hepatology and The FASEB Journal.

In The Last Decade

Riccardo Perbellini

38 papers receiving 773 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Riccardo Perbellini Italy	14	420	397	311	165	67	40	781
N. Tono Italy	10	317 0.8×	337 0.8×	101 0.3×	44 0.3×	6 0.1×	18	492
Milad Rezvani United States	8	173 0.4×	431 1.1×	317 1.0×	23 0.1×	16 0.2×	17	803
Xuzhen Yan China	10	125 0.3×	121 0.3×	129 0.4×	42 0.3×	10 0.1×	18	337
Wenfeng Feng China	12	167 0.4×	83 0.2×	106 0.3×	49 0.3×	12 0.2×	49	532
Ping‐Fang Hu China	13	93 0.2×	94 0.2×	217 0.7×	94 0.6×	4 0.1×	20	410
Jung‐Chin Chang Netherlands	11	75 0.2×	115 0.3×	130 0.4×	31 0.2×	16 0.2×	23	336
Michihiko Takesue Japan	13	99 0.2×	205 0.5×	96 0.3×	13 0.1×	24 0.4×	18	355
Ana Oteiza Norway	11	97 0.2×	81 0.2×	99 0.3×	44 0.3×	4 0.1×	18	398
Adi Egozi Israel	7	84 0.2×	80 0.2×	245 0.8×	45 0.3×	5 0.1×	13	475
Wendong Chen China	5	208 0.5×	157 0.4×	115 0.4×	30 0.2×	4 0.1×	15	374

Countries citing papers authored by Riccardo Perbellini

Since Specialization

Citations

This map shows the geographic impact of Riccardo Perbellini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Riccardo Perbellini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Riccardo Perbellini more than expected).

Fields of papers citing papers by Riccardo Perbellini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Riccardo Perbellini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Riccardo Perbellini. The network helps show where Riccardo Perbellini may publish in the future.

Co-authorship network of co-authors of Riccardo Perbellini

This figure shows the co-authorship network connecting the top 25 collaborators of Riccardo Perbellini. A scholar is included among the top collaborators of Riccardo Perbellini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Riccardo Perbellini. Riccardo Perbellini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Iavarone, Massimo, Riccardo Perbellini, Sara Uceda Renteria, et al.. (2024). ASAP score may predict HCC recurrence after complete radiological response to locoregional treatments. Digestive and Liver Disease. 56. S89–S89. 1 indexed citations

Caviglia, Gian Paolo, Piero Fariselli, Roberta D’Ambrosio, et al.. (2024). Development and Validation of a PIVKA‐II‐Based Model for HCC Risk Stratification in Patients With HCV‐Related Cirrhosis Successfully Treated With DAA. Alimentary Pharmacology & Therapeutics. 61(3). 538–549. 2 indexed citations

Renteria, Sara Uceda, Elisabetta Degasperi, Marta Borghi, et al.. (2024). Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods. Liver International. 44(3). 831–837. 4 indexed citations

Toniutto, Pierluigi, Edmondo Falleti, Sara Cmet, et al.. (2024). Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide. Journal of Hepatology. 81(5). 819–826. 5 indexed citations

Renteria, Sara Uceda, Elisabetta Degasperi, F. Facchetti, et al.. (2024). Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV. JHEP Reports. 7(3). 101299–101299. 3 indexed citations

Degasperi, Elisabetta, Sara Uceda Renteria, Marta Borghi, et al.. (2023). Pretreatment and on-therapy HDV RNA levels predict response to Bulevirtide monotherapy in HDV compensated cirrhotic patients treated up to 96 weeks. Journal of Hepatology. 78. S1159–S1159. 1 indexed citations

Loglio, Alessandro, Giulia Tosetti, Elisabetta Degasperi, et al.. (2023). Long‐term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years. Alimentary Pharmacology & Therapeutics. 57(12). 1407–1416. 1 indexed citations

Degasperi, Elisabetta, Sara Uceda Renteria, Marta Borghi, et al.. (2022). Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. Journal of Hepatology. 77(6). 1525–1531. 42 indexed citations

Shekhtman, Louis, Harel Dahari, Scott J. Cotler, et al.. (2022). Most patients with advanced cirrhosis treated with bulevirtide monotherapy have a non-monophasic HDV RNA decline patterns: an interim kinetic analysis of real-life setting. Journal of Hepatology. 77. S874–S874. 1 indexed citations

10.

Iavarone, Massimo, Giulia Tosetti, F. Facchetti, et al.. (2022). Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study. Digestive and Liver Disease. 55(2). 160–168. 13 indexed citations

11.

D’Ambrosio, Roberta, Riccardo Perbellini, Elisabetta Degasperi, et al.. (2022). Diabetes and number of metabolic risk factors influence liver disease severity in patients with non-alcoholic fatty liver disease. Digestive and Liver Disease. 54. S35–S36. 1 indexed citations

12.

Colucci, Giuseppe, Federica Invernizzi, Sara Uceda Renteria, et al.. (2021). The CCR5 and CXCR3 Pathways in Hepatitis C Virus Liver Transplanted Recipients Treated by a Direct Antiviral Agent Regimen: Informative Kinetics Profiles. Viral Immunology. 34(8). 542–551. 3 indexed citations

13.

D’Ambrosio, Roberta, Elisabetta Degasperi, Marta Borghi, et al.. (2021). Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. Journal of Hepatology. 76(2). 302–310. 49 indexed citations

14.

D’Ambrosio, Roberta, Irene Campi, Marco Maggioni, et al.. (2021). The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD). PLoS ONE. 16(4). e0249614–e0249614. 19 indexed citations

15.

Varchetta, Stefania, Dalila Mele, Roberta D’Ambrosio, et al.. (2021). A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. Journal of Viral Hepatitis. 28(10). 1443–1451. 2 indexed citations

16.

Loglio, Alessandro, Péter Ferenci, C Tham, et al.. (2020). Safety and efficacy of up to 76 weeks 10 mg/day (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis. Digestive and Liver Disease. 52. e28–e29. 1 indexed citations

17.

D’Ambrosio, Roberta, Elisabetta Degasperi, Massimo Iavarone, et al.. (2018). Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3 year study. Journal of Hepatology. 68. S529–S529. 4 indexed citations

18.

Romeo, R., Arnolfo Petruzziello, Eve‐Isabelle Pécheur, et al.. (2018). Hepatitis delta virus and hepatocellular carcinoma: an update. Epidemiology and Infection. 146(13). 1612–1618. 34 indexed citations

19.

Galmozzi, E., F. Facchetti, Riccardo Perbellini, & Alessio Aghemo. (2014). High-resolution melting assay for genotyping of IFNL4-associated dinucleotide variant rs368234815. Clinical Microbiology and Infection. 20(11). O936–O938. 3 indexed citations

20.

Perbellini, Riccardo, Simona Greco, Rosanna Cardani, et al.. (2010). Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscular Disorders. 21(2). 81–88. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact